With a pilot study complete, scientists from GATC Biotech subsidiary LifeCodexx have started the clinical validation study of a sequencing-based trisomy 21 test, which it plans to launch by the end of the year.

The company will conduct the clinical validation study on 500 samples in conjunction with several European prenatal centers on the Illumina HiSeq 2000. In a statement, CEO Michael Lutz said the researchers would pool up to seven samples, which would help cut costs by 50 percent.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.